To Bring New Treatment Options and Renewed Hope to Patients Navigating Cancers with the Greatest Medical Need
For cancer patients, finding out that their current medication is no longer effective and that viable options are either limited or ineffective can be devastating. Yet this is what patients and clinicians are facing all too frequently.
At Cardiff Oncology, our mission is to turn the tide on cancer by developing onvansertib, a first-in-class, third generation Polo-like Kinase 1 (PLK1) inhibitor, to treat cancers with the greatest medical need for new therapeutic options to overcome resistance, improve response and increase overall survival.
Onvansertib, our investigational drug, is demonstrating safety and clinical benefit in all three of our ongoing clinical trials.